FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 227 filers reported holding FATE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $815,202 | -43.9% | 171,261 | -32.8% | 0.04% | -51.1% |
| Q1 2023 | $1,453,437 | +1187.2% | 254,989 | +2178.5% | 0.09% | +1185.7% |
| Q4 2022 | $112,917 | -54.1% | 11,191 | +2.1% | 0.01% | -61.1% |
| Q3 2022 | $246,000 | -10.9% | 10,962 | -1.7% | 0.02% | 0.0% |
| Q2 2022 | $276,000 | -43.1% | 11,154 | -10.8% | 0.02% | -10.0% |
| Q1 2022 | $485,000 | -40.4% | 12,511 | -10.1% | 0.02% | -25.9% |
| Q4 2021 | $814,000 | -11.3% | 13,911 | -10.2% | 0.03% | -12.9% |
| Q3 2021 | $918,000 | +350.0% | 15,495 | +558.2% | 0.03% | +342.9% |
| Q2 2021 | $204,000 | – | 2,354 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |